Nerve Hydrodissection with 5% Dextrose: Injection therapy
Study summary
Comparison of the effectiveness of nerve hydrodissection with saline injection of 5% dextrose in carpal tunnel syndrome.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Adults aged 18-80 years
* Clinical and electrophysiological diagnosis of mild to moderate carpal tunnel syndrome
* Symptom duration of at least 3 months
* Both male and female participants
* Patients who have not responded adequately to conservative treatment
* Patients who do not wish to undergo surgical treatment
* Ability to provide informed consent
Exclusion Criteria:
* Severe or very severe carpal tunnel syndrome based on EMG findings
* Previous injection therapy for carpal tunnel syndrome
* Prior wrist or carpal tunnel surgery
* Polyneuropathy or other peripheral neuropathies
* Cervical radiculopathy or proximal median nerve entrapment
* Brachial plexopathy or thoracic outlet syndrome
* Pregnancy
* Malignancy
* Local or systemic infection
* Cognitive impairment affecting cooperation
* Systemic diseases affecting the median nerve (e.g., uncontrolled diabetes mellitus, thyroid disorders)
Primary outcome measure(s)
Change in pain intensity measured by Visual Analog Scale (VAS) — Baseline to 8 month The primary outcome is the change in pain intensity assessed by the Visual Analog Scale (VAS, 0-10). The difference between baseline and follow-up scores will be analyzed.
Trial sites (1)
Facility
City
Region
Status
Antalya Eğitim Araştırma Hastanesi
Antalya
Turkey (Türkiye)
More Antalya Training and Research Hospital trials in Turkey
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.